Written by Partha Nandi, MD, FACP
Researchers testing a new celiac disease drug called FB102 reported that it helped protect the small intestine from gluten damage in a mid-stage trial. In 126 adults with celiac disease, the drug preserved the gut lining better than a placebo while everyone ate gluten on purpose under medical supervision. For a condition that still has no approved medicine, that caught my eye.
A few caveats before anyone gets ahead of the news. These are early, topline results that haven’t been peer-reviewed yet, the drug isn’t approved, and it does not hand anyone with celiac disease a pass to eat gluten. What it offers is a real step toward a treatment that might one day sit alongside the gluten-free diet rather than replace it.
I’ll walk you through what the trial tested, how the drug works, and what it means for you if you or someone you love is living with celiac disease.
Dr. Nandi’s Bottom Line
A new drug called FB102 helped shield the gut lining from gluten damage in a phase 2 celiac trial. The result is promising and early, not a finished treatment, and the drug isn’t approved. Nothing changes today. A strict gluten-free diet is still the only treatment, so if you have celiac disease, stay on it and ask your doctor about clinical trials.
Why a Gluten-Free Diet Isn’t Always Enough
Celiac disease is an autoimmune condition. When a person with celiac eats gluten, the immune system attacks the lining of the small intestine, and even a small amount can cause damage.
The damage is specific. The small intestine is lined with tiny, finger-like projections called villi, which absorb nutrients from food. In people with celiac disease, gluten shortens these projections and deepens the grooves between them. Less surface area means less absorption, and over time that can lead to nutritional deficiencies.
Right now, the only treatment is a strict gluten-free diet. It works, but it leaves very little room for error. Even when people check every label, accidental exposure happens, and the diet doesn’t fully control symptoms for everyone. Symptoms persist in up to 40 percent of patients.
That is the gap researchers are trying to close. No approved drug can currently protect the gut from accidental gluten exposure. Several experimental drugs are being tested, and one of them has just cleared a phase 2 trial.
A Closer Look at the FB102 Trial
Researchers enrolled 126 adults with confirmed celiac disease. All of them had followed a strict gluten-free diet for at least a year and had no symptoms going in.
They were randomly assigned, in a two-to-two-to-one split, to one of two FB102 doses given by IV infusion or to a placebo infusion with no active drug. Neither the patients nor the researchers knew who got what, which keeps expectations from coloring the results. For eight weeks, everyone ate gluten on purpose under controlled conditions. The question was straightforward: could the drug shield the gut while it was being exposed to gluten?
To measure that, the team compared the height of the villi against the depth of the grooves beneath them, a biopsy-based ratio that drops as gluten flattens the lining. At day 78, that ratio held up significantly better in the FB102 groups than in the placebo group. The result reached statistical significance (p=0.0176), meaning the difference was unlikely to be chance. People on FB102 also showed fewer signs of gluten injury and a smaller inflammatory response in the gut lining, and no new safety concerns turned up.
A word of caution on how to read this. A p-value tells you a difference probably wasn’t luck. It doesn’t tell you how large the benefit was or how much a patient would feel it. These are topline numbers released by argenx, the company developing the drug, and the full results haven’t been published or peer-reviewed yet. The trial also enrolled only people who were symptom-free on the diet, so we don’t know how FB102 performs in those whose symptoms persist.
How FB102 Works
FB102 is an antibody, a lab-made protein designed to attach to one specific target. That target is CD122, a receptor on the surface of certain immune cells. Think of a receptor as a docking point: when an inflammatory signal attaches to it, the cell gets the message to act.
CD122 picks up signals from two messengers called IL-2 and IL-15, which help activate and sustain the immune cells that drive disease. Researchers believe these signals play a central role in how celiac disease starts and keeps going. In 2009, a study showed that blocking this receptor in mice with autoimmune gut problems reversed their intestinal damage. That finding led to the idea of testing the same approach in people with celiac disease.
FB102 was built to block CD122 on only some of the immune cells that cause trouble, and to leave it working on others. The company says this preserves the regulatory T cells, which help keep the immune system in balance. The goal is to calm the faulty response to gluten without shutting down immune defenses more broadly.
The drug was developed by Forte Biosciences, which argenx acquired in August 2026. Before the phase 2 trial, an earlier phase 1b study had already pointed in the same direction, showing that blocking CD122 protected against gluten-induced gut damage and prevented symptoms. The FDA has also granted FB102 Fast Track designation for celiac disease, a status that speeds up development and review of drugs for serious conditions with few or no treatment options.
Promising, but Not a Green Light to Eat Gluten
FB102 doesn’t give people with celiac disease permission to eat gluten freely. The drug was tested under controlled conditions, and it’s unclear whether the protection holds in daily life, where exposure is accidental and varies in amount.
The data also have limits. These are topline results announced by argenx, and they haven’t been peer-reviewed. The company hasn’t shared how large the effect was, how the two doses compared, or the detailed secondary results. A significant p-value tells us the difference was probably not due to chance. It doesn’t tell us how much it matters to a patient. The trial also enrolled only people who were symptom-free on a gluten-free diet, so we don’t know how the drug works in people whose symptoms persist despite the diet.
Full results are expected at an upcoming medical meeting, and argenx plans to move FB102 into phase 3. The bar for approval is high. According to the FDA’s draft guidance, a drug taken long term would need to show efficacy over at least 52 weeks, and without a gluten challenge. This trial’s challenge lasted eight weeks.
The research isn’t limited to celiac disease. FB102 is also being studied in vitiligo, a condition in which skin loses its pigment in patches, and researchers suspect it could help with alopecia areata, an autoimmune cause of hair loss. If the CD122 approach holds up, it could apply to several immune-driven conditions.
For patients today, nothing changes. Stay on a strict gluten-free diet and talk to your doctor before changing how you manage your condition.
My Personal RX on Protecting Your Gut Every Day
Whether you have celiac disease, a gluten sensitivity, or simply want better digestion, the lining of your small intestine matters. It absorbs the nutrients your body needs. Drugs like FB102 are still in testing, so daily habits do the heavy lifting right now.
Here are my personal tips.
- Get Tested Before You Cut Gluten: Going gluten-free first can make celiac disease harder to diagnose. See your doctor before changing your diet.
- Read Every Label: Gluten shows up in sauces, soups, and processed foods. Recipes change, so check each time.
- Prevent Cross-Contact: Use separate toasters, cutting boards, and colanders at home. At restaurants, ask how your food is prepared.
- Lean on Naturally Gluten-Free Foods: Vegetables, fruit, eggs, fish, and rice need no label decoding.
- Check for Nutrient Gaps: Gut damage can lower your absorption of iron, calcium, and vitamin D. Ask your doctor to check your levels.
- Support Your Digestion: My Gut Brain Reset Bundle combines MindBiotic, Digestive Enzymes, and Eye Max to support digestion, microbiome balance, and nutrient absorption. Supplements support your gut, but they don’t replace a gluten-free diet if you have celiac disease.
- Manage Stress: Stress can aggravate digestive symptoms through the gut-brain axis. Try deep breathing or a daily walk.
- Prioritize Sleep: Aim for seven to nine hours. Your gut and immune system both need the rest.
- Learn the Science: My book, Heal Your Gut, Save Your Brain, explains how gut health shapes mood and cognition.
- Stay on the Diet: FB102 is promising but not approved. Until your doctor says otherwise, a strict gluten-free diet remains the treatment. Ask your doctor about new trials.
When to See a Doctor
Celiac disease is manageable, but it still needs regular medical follow-up, and a few symptoms are worth a prompt call rather than a wait-and-see. Check in with your doctor if you notice:
- Symptoms that persist or come back even though you’re sticking to a strict gluten-free diet
- Unexplained weight loss, or ongoing diarrhea that won’t settle
- Signs of anemia, such as unusual tiredness, paleness, or getting winded easily
- Bone pain, or fractures from minor bumps, which can point to poor calcium or vitamin D absorption
- Severe or persistent abdominal pain
- New digestive symptoms after a long stretch of feeling well on the diet
None of these means something is seriously wrong, but they’re worth checking so your doctor can look for the cause and keep your gut on track.
References:
- argenx. (2026, October 8). argenx announces positive topline results from Phase 2 study of FB102 in celiac disease[Press release]. https://argenx.com/news/2026/press-release-3376936
- National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Celiac disease. U.S. Department of Health and Human Services, National Institutes of Health. https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease
- U.S. Food and Drug Administration. (2022). Celiac disease: Developing drugs for adjunctive treatment to a gluten-free diet [Draft guidance for industry]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/celiac-disease-developing-drugs-adjunctive-treatment-gluten-free-diet
- Yokoyama, S., Watanabe, N., Sato, N., Perera, P.-Y., Filkoski, L., Tanaka, T., Miyasaka, M., Waldmann, T. A., Hiroi, T., & Perera, L. P. (2009). Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. Proceedings of the National Academy of Sciences, 106(37), 15849–15854. https://doi.org/10.1073/pnas.0908834106
- ClinicalTrials.gov. (2025). A study to evaluate the efficacy and safety of FB102 in adults with celiac disease (FB102-301) (NCT06982963). U.S. National Library of Medicine. https://clinicaltrials.gov/study/NCT06982963
Frequently Asked Questions
Is FB102 available to patients now?
No. FB102 is investigational, which means it’s still being studied and hasn’t been approved by the FDA for celiac disease or any other condition. It has cleared a phase 2 trial, and argenx plans to test it in a larger phase 3 study. An approval, if it comes, would be years away.
Will this drug let me eat gluten again?
No. FB102 was tested as added protection while patients stayed on a gluten-free diet, not as a replacement for it. The trial used a controlled gluten challenge in a clinical setting, which isn’t the same as eating gluten freely in daily life. Even if the drug is approved someday, the gluten-free diet is expected to remain the foundation of treatment.
How is FB102 different from the gluten-free diet?
The diet works by removing the trigger, gluten, so the immune system has nothing to react to. FB102 works further downstream, by blocking an immune signal through a target called CD122 that drives the gut damage. The idea is to add a layer of protection for the accidental exposures the diet can’t fully prevent.
What can I do while treatments like this are still being studied?
Stay on a strict gluten-free diet, keep up with your medical follow-up, and have your doctor check for nutrient gaps like iron and vitamin D. If you want to be part of the research, ask your doctor whether a clinical trial is a good fit for you.











